New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk classification system that groups prostate cancer patients based on their risk of recurrence.
The Society of Nuclear Medicine and Molecular Imaging lauds last week’s decision by the Centers for Medicare & Medicaid Services to remove exclusionary language relating to the non-oncologic use of PET, expanding access to critical care for patients.
Researchers have developed an approach to estimating when a person who is likely to develop Alzheimer’s disease, but has no cognitive symptoms, will start showing signs of Alzheimer’s dementia.
The effects of COVID-19 on the brain can be accurately measured with PET, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
Read More
PET using a 68Ga-labeled fibroblast activation protein inhibitor can noninvasively identify and monitor pulmonary fibrosis, according to new research.
Read More
A new imaging technique has the potential to detect neurological disorders—such as Alzheimer’s disease—at their earliest stages, enabling physicians to diagnose and treat patients more quickly.
Read More
Bringing the capabilities of artificial intelligence to molecular imaging, Advanced intelligent Clear-IQ Engine, Canon Medical Systems USA Inc.’s Deep Learning Reconstruction technology, is now U.S. FDA 510(k) cleared on the Cartesion Prime Digital PET/CT system.
Read More
The targeted radionuclide therapy 177Lu-PSMA-617 has been proven effective in improving survival in men with advanced prostate cancer, according to recently published results from the VISION trial.
Read More